


# ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I



5 or a pharmaceutically acceptable salt thereof,  
wherein R<sup>1</sup>, Q, Y<sup>2</sup>, Y<sup>3</sup>, Y<sup>4</sup>, U<sup>5</sup>, U<sup>6</sup>, U<sup>8</sup>, and R<sup>2</sup> are as defined in the  
specification. The invention also provides pharmaceutical compositions  
comprising a compound of Formula I, or a pharmaceutically acceptable salt  
thereof, as defined in the specification, together with a pharmaceutically  
10 acceptable carrier, diluent, or excipient. The invention also provides methods of  
inhibiting an MMP-13 enzyme in an animal, comprising administering to the  
animal a compound of Formula I, or a pharmaceutically acceptable salt thereof.  
The invention also provides methods of treating a disease mediated by an MMP-  
13 enzyme in a patient, comprising administering to the patient a compound of  
15 Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a  
pharmaceutical composition. The invention also provides methods of treating  
diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis,  
arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,  
inflammatory bowel disease, heart failure, age-related macular degeneration,  
20 chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis,  
atherosclerosis, and osteoporosis in a patient, comprising administering to the  
patient a compound of Formula I, or a pharmaceutically acceptable salt thereof,  
either alone or in a pharmaceutical composition. The invention also provides  
combinations, comprising a compound of Formula I, or a pharmaceutically  
25 acceptable salt thereof, together with another pharmaceutically active component  
as described in the specification.